Dr. Robert A. Hauser of the University of South Florida and his team have identified three new promising treatments for Parkinson's patients.
Parkinson's disease, which affects the motor coordination causing shaking and difficulty in movements, has no known cure and only the symptoms can be treated. Dr. Robert Hauser and his team in their studies looked at improving the treatment methodologies by using new drugs.
Study-I
New Family of Compounds Provide Hope for Parkinson’s Disease Patients
Researchers at Northwestern University have developed a new family of compounds that could help slow down the progression of Parkinson's disease.
Advertisement
Levodopa, is the commonly used drug to control motor symptoms. This drug remains ineffective for up to six hours between doses. In the first randomized study involving 420 patients, researchers treated the patients with a new trial drug, tozadenant, along with levodopa. After 12 weeks, it was found that the wear-off time was reduced by more than an hour along with reduced involuntary tremors.
Study-II
Another common problem is the sudden drop in blood pressure when the patient stands up from sitting position as norepinephrine, a brain signaling chemical is not released. This often caused the patients to fall. In the next randomized trial involving 225 patients, researchers administered drug droxidopa (L-DOPS) and placebo randomly. After 10 weeks, it was noted that patients on droxidopa were less likely to fall and drop in blood pressure was reduced.
![US FDA Approves Generic Version of Wockhardt’s Drug to Treat Parkinson’s Disease]( "US FDA Approves Generic Version of Wockhardt’s Drug to Treat Parkinson’s Disease")
Wockhardt Ltd got US FDA approval to market the generic version of Ropinirole extended release tablets for the treatment of Parkinson's disease.
Study -III
In his third study, Hauser examined 321 patients in the early stages of Parkinson's disease who did not respond to dopamine agonist drug, generally given to patients with initial stages of the disease. Patients were randomly assigned to the drug rasagiline or a placebo and at after 18 weeks it was found that the severity of the disease decreased in patients who were on rasagiline.
Dr. Robert A. Hauser will present the findings of the three successful studies at the American Academy of Neurology's 65th Annual Meeting in San Diego next week.
Source: Medindia
Another common problem is the sudden drop in blood pressure when the patient stands up from sitting position as norepinephrine, a brain signaling chemical is not released. This often caused the patients to fall. In the next randomized trial involving 225 patients, researchers administered drug droxidopa (L-DOPS) and placebo randomly. After 10 weeks, it was noted that patients on droxidopa were less likely to fall and drop in blood pressure was reduced.
US FDA Approves Generic Version of Wockhardt’s Drug to Treat Parkinson’s Disease
Wockhardt Ltd got US FDA approval to market the generic version of Ropinirole extended release tablets for the treatment of Parkinson's disease.
Advertisement
Study -III
In his third study, Hauser examined 321 patients in the early stages of Parkinson's disease who did not respond to dopamine agonist drug, generally given to patients with initial stages of the disease. Patients were randomly assigned to the drug rasagiline or a placebo and at after 18 weeks it was found that the severity of the disease decreased in patients who were on rasagiline.
Dr. Robert A. Hauser will present the findings of the three successful studies at the American Academy of Neurology's 65th Annual Meeting in San Diego next week.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial